tbuckley/cabot-search huggingface dataset:
The effectiveness of social network interventions for psychiatric patients: A systematic review and meta-analysis
Authors: L.T.A. Swinkels, M. Hoeve, J.F. ter Harmsel, L.J. Schoonmade, J.J.M. Dekker, A. Popma, T.M. van der Pol
Journal: Clinical Psychology Review (2023)

Strengthening social networks is an important goal in mental health treatment. This study aimed to determine the effectiveness of social network interventions for psychiatric patients. A systematic review and meta-analysis was conducted comparing these interventions with control groups on social and mental health-related outcomes in psychiatric patients. PubMed, EMBASE.com, PsycInfo, Scopus, and IBSS were searched for studies until December 21, 2022. Three-level random effects models were used to obtain Cohen's d mean estimates on composite outcomes of social network, and secondary mental health outcomes. Heterogeneity was examined with potential moderators. Thirty-three studies were included. Small-to-moderate effects of social network interventions were detected on positive social network (d = 0.115, p = 0.022) and support (d = 0.159; p = 0.007), general functioning (d = 0.127, p = 0.046), mental health treatment adherence (d = 0.332, p = 0.003), days substance use (d = 0.097, p = 0.004), and abstinence (d = 0.254, p = 0.004). Estimates of psychiatric functioning were higher in samples with more females. The quality of evidence was moderate-to-low. This evidence suggests that social network interventions can improve positive social networks, general functioning, mental health treatment adherence, and substance use in psychiatric patients receiving usual care. PROSPERO ID: CRD42019131959.
Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry
Authors: Sarah M. Pearsall, Stuart C. Williamson, Sam Humphrey, Ellyn Hughes, Derrick Morgan, Fernando J. García Marqués, Griselda Awanis, Rebecca Carroll, Laura Burks, Yan Ting Shue, Abel Bermudez, Kristopher K. Frese, Melanie Galvin, Mathew Carter, Lynsey Priest, Alastair Kerr, Cong Zhou, Trudy G. Oliver, Jonathan D. Humphries, Martin J. Humphries, Fiona Blackhall, Ian G. Cannell, Sharon J. Pitteri, Gregory J. Hannon, Julien Sage, Caroline Dive, Kathryn L. Simpson
Journal: Journal of Thoracic Oncology (2023)

Vasculogenic mimicry (VM), the process of tumor cell transdifferentiation to endow endothelial-like characteristics supporting de novo vessel formation, is associated with poor prognosis in several tumor types, including SCLC. In genetically engineered mouse models (GEMMs) of SCLC, NOTCH, and MYC co-operate to drive a neuroendocrine (NE) to non-NE phenotypic switch, and co-operation between NE and non-NE cells is required for metastasis. Here, we define the phenotype of VM-competent cells and molecular mechanisms underpinning SCLC VM using circulating tumor cell-derived explant (CDX) models and GEMMs.
Oxidative stress, the blood–brain barrier and neurodegenerative diseases: The critical beneficial role of dietary antioxidants
Authors: Jin Feng, Youle Zheng, Mingyue Guo, Irma Ares, Marta Martínez, Bernardo Lopez-Torres, María-Rosa Martínez-Larrañaga, Xu Wang, Arturo Anadón, María-Aránzazu Martínez
Journal: Acta Pharmaceutica Sinica B (2023)

In recent years, growing awareness of the role of oxidative stress in brain health has prompted antioxidants, especially dietary antioxidants, to receive growing attention as possible treatments strategies for patients with neurodegenerative diseases (NDs). The most widely studied dietary antioxidants include active substances such as vitamins, carotenoids, flavonoids and polyphenols. Dietary antioxidants are found in usually consumed foods such as fresh fruits, vegetables, nuts and oils and are gaining popularity due to recently growing awareness of their potential for preventive and protective agents against NDs, as well as their abundant natural sources, generally non-toxic nature, and ease of long-term consumption. This review article examines the role of oxidative stress in the development of NDs, explores the ‘two-sidedness’ of the blood–brain barrier (BBB) as a protective barrier to the nervous system and an impeding barrier to the use of antioxidants as drug medicinal products and/or dietary antioxidants supplements for prevention and therapy and reviews the BBB permeability of common dietary antioxidants suplements and their potential efficacy in the prevention and treatment of NDs. Finally, current challenges and future directions for the prevention and treatment of NDs using dietary antioxidants are discussed, and useful information on the prevention and treatment of NDs is provided.
Common Sense Oncology: outcomes that matter
Authors: Christopher M Booth, Manju Sengar, Aaron Goodman, Brooke Wilson, Ajay Aggarwal, Scott Berry, David Collingridge, Avram Denburg, Elizabeth A Eisenhauer, Ophira Ginsburg, Daniel Goldstein, Sanjeeva Gunasekera, Nazik Hammad, Kazunori Honda, Christopher Jackson, Deme Karikios, Kevin Knopf, Rachel Koven, Bernard L Marini, Deborah Maskens, Fabio Y Moraes, Ghulam Rehman Mohyuddin, Bishesh Sharma Poudyal, C S Pramesh, Felipe Roitberg, Fidel Rubagumya, Sally Schott, Bhawna Sirohi, Enrique Soto-Perez-de-Celis, Richard Sullivan, Ian F Tannock, Dario Trapani, Michelle Tregear, Winette van der Graaf, Verna Vanderpuye, Bishal Gyawali
Journal: The Lancet Oncology (2023)
Hepatocyte-secreted FAM3D ameliorates hepatic steatosis by activating FPR1-hnRNP U-GR-SCAD pathway to enhance lipid oxidation
Authors: Yuntao Hu, Jing Li, Xin Li, Di Wang, Rui Xiang, Wenjun Liu, Song Hou, Qinghe Zhao, Xiaoxing Yu, Ming Xu, Dong Zhao, Tao Li, Yujing Chi, Jichun Yang
Journal: Metabolism (2023)
Hospital stays and costs of telemedical monitoring versus standard follow-up for diabetic foot ulcer: an open-label randomised controlled study
Authors: Dured Dardari, Sylvia Franc, Guillaume Charpentier, Laurent Orlando, Elise Bobony, Marie Bouly, Ilham Xhaard, Zohra Amrous, Khadijatou Ly Sall, Bruno Detournay, Alfred Penfornis
Journal: The Lancet Regional Health - Europe (2023)

Two randomised controlled trials (RCTs) have previously shown that telemedical monitoring of diabetic foot ulcer (DFU) reduces the number of visits to the outpatient clinic, without losing treatment efficacy or increasing costs. Here we present the results of an open-label, randomised controlled trial designed to investigate whether telemonitoring, provided by an expert nurse (with extensive experience in DFU and trained in remote monitoring), reduces the hospital stay and the associated costs for a patient with DFU (TELEPIED trial).Eligible patients (n = 180) were randomly allocated to: (i) a control group, in which they received standard care, and (ii) an intervention group, in which they received asynchronous telemedicine follow-up by the expert nurse. The primary outcome was the cumulative hospital days over 12 months. The main secondary outcomes were (i) direct healthcare costs (estimated in a collective perspective), (ii) wound healing and (iii) amputation rates. ITT (intention-to-treat) population was analysed.In the ITT population, cumulative hospital days were significantly higher in the control group (13.4 days [95% CI 9.0-17.8]) than in the intervention group (7.1 days [2.8-11.5]) (p = 0.0458, ANCOVA model). Cumulative direct costs over 12 months were 7185 € (95% CI 5144-9226) in the control group and 3471 € (95% CI 1430-5512) in the intervention group (p = 0.0120). The percentage of wounds healed and amputation rate were not significantly different between groups. Similar results were found with the PP population.The implementation of a telemedical intervention with an expert nurse could lead to a length of hospitalization and direct costs that were two times lower compared to conventional follow-up. This lower medical and economic burden was obtained without losing effectiveness on the rate of healing, nor increasing the amputation rate. Additional studies are required to confirm these findings.This study was designed, funded and conducted by CERITD (Study and Research Centre for Intensification of Diabetes Treatment, Evry, France), Genopole GIP, 20 rue Henri Desbruères, 91030 EVRY Cedex and Laboratoires URGO, 15 Avenue d'Iéna, 75116 Paris Cedex, France. The findings and conclusions in this study are those of the authors and do not necessarily represent the views of the sponsor. The corresponding author (DD) certify that authors were not precluded from accessing data in the study, and they accept responsibility to submit for publication.
Pulmonary rehabilitation: Publication rate of presentations to international congresses: Are the abstracts being published as journal articles?
Authors: G. da Silva Gonçalves, E.F. Timóteo, D.F. da Silva, M.J.X. Ribeiro, T.M.D. Oliveira, A. José, C.C. Oliveira, C. Malaguti
Journal: Pulmonology (2023)
Baseline dependent minimally important differences for clinical outcomes of pulmonary rehabilitation in people with COPD
Authors: A.R. Jenkins, M.T.J. Groenen, A.W. Vaes, D.J.A. Janssen, E.F.M. Wouters, F.M.E. Franssen, M.A. Spruit
Journal: Pulmonology (2023)

Minimally important differences (MIDs) for common outcomes of pulmonary rehabilitation are well documented for people with chronic obstructive pulmonary disease (COPD). It is not known whether MIDs differ based on COPD disease characteristics. This study aimed to estimate MIDs for clinical outcomes of pulmonary rehabilitation dependent upon baseline characteristics.
FUS-mediated HypEVs: Neuroprotective effects against ischemic stroke
Authors: Yousheng Wu, Xiaoxiong Huang, Zefeng Tan, Jiankun Zang, Min Peng, Niu He, Tao Zhang, Hongcheng Mai, Anding Xu, Dan Lu
Journal: Bioactive Materials (2023)

Few studies have investigated the properties and protein composition of small extracellular vesicles (sEVs) derived from neurons under hypoxic conditions. Presently, the extent of the involvement of these plentiful sEVs in the onset and progression of ischemic stroke remains an unresolved question. Our study systematically identified the characteristics of sEVs derived from neurons under hypoxic conditions (HypEVs) by physical characterization, sEV absorption, proteomics and transcriptomics analysis. The effects of HypEVs on neurites, cell survival, and neuron structure were assessed in vitro and in vivo by neural complexity tests, magnetic resonance imaging (MRI), Golgi staining, and Western blotting of synaptic plasticity-related proteins and apoptotic proteins. Knockdown of Fused in Sarcoma (FUS) small interfering RNA (siRNA) was used to validate FUS-mediated HypEV neuroprotection and mitochondrial mRNA release. Hypoxia promoted the secretion of sEVs, and HypEVs were more easily taken up and utilized by recipient cells. The MRI results illustrated that the cerebral infarction volume was reduced by 45% with the application of HypEVs, in comparison to the non- HypEV treatment group. Mechanistically, the FUS protein is necessary for the uptake and neuroprotection of HypEVs against ischemic stroke as well as carrying a large amount of mitochondrial mRNA in HypEVs. However, FUS knockdown attenuated the neuroprotective rescue capabilities of HypEVs. Our comprehensive dataset clearly illustrates that FUS-mediated HypEVs deliver exceptional neuroprotective effects against ischemic stroke, primarily through the maintenance of neurite integrity and the reduction of mitochondria-associated apoptosis.
Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)
Authors: Simone Cesaro, Malgorzata Mikulska, Hans H. Hirsch, Jan Styczynski, Sylvain Meylan, Catherine Cordonnier, Davide Navarro, Marie von Lilienfeld-Toal, Varun Mehra, Francesco Marchesi, Caroline Besson, Raul Cordoba Masculano, Gernot Beutel, Herman Einsele, Johan Maertens, Rafael de la Camara, Marie von Lilienfeld-Toal, Rafael de la Camara, Per Ljungman, Livio Pagano
Journal: Leukemia (2023)
Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report
Authors: Cindy Im, Noha Sharafeldin, Yan Yuan, Zhaoming Wang, Yadav Sapkota, Zhanni Lu, Logan G. Spector, Rebecca M. Howell, Michael A. Arnold, Melissa M. Hudson, Kirsten K. Ness, Leslie L. Robison, Smita Bhatia, Gregory T. Armstrong, Joseph P. Neglia, Yutaka Yasui, Lucie M. Turcotte
Journal: Journal of Clinical Oncology (2023)

Chemotherapeutic exposures are associated with subsequent malignant neoplasm (SMN) risk. The role of genetic susceptibility in chemotherapy-related SMNs should be defined as use of radiation therapy (RT) decreases.SMNs among long-term childhood cancer survivors of European (EUR; N = 9,895) and African (AFR; N = 718) genetic ancestry from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study were evaluated. An externally validated 179-variant polygenic risk score (PRS) associated with pleiotropic adult cancer risk from the UK Biobank Study (N > 400,000) was computed for each survivor. SMN cumulative incidence comparing top and bottom PRS quintiles was estimated, along with hazard ratios (HRs) from proportional hazards models.A total of 1,594 survivors developed SMNs, with basal cell carcinomas (n = 822), breast cancers (n = 235), and thyroid cancers (n = 221) being the most frequent. Although SMN risk associations with the PRS were extremely modest in RT-exposed EUR survivors (HR, 1.22; P = .048; n = 4,630), the increase in 30-year SMN cumulative incidence and HRs comparing top and bottom PRS quintiles was statistically significant among nonirradiated EUR survivors (n = 4,322) treated with alkylating agents (17% v 6%; HR, 2.46; P < .01), anthracyclines (20% v 8%; HR, 2.86; P < .001), epipodophyllotoxins (23% v 1%; HR, 12.20; P < .001), or platinums (46% v 7%; HR, 8.58; P < .01). This PRS also significantly modified epipodophyllotoxin-related SMN risk among nonirradiated AFR survivors (n = 414; P < .01). Improvements in prediction attributable to the PRS were greatest for epipodophyllotoxin-exposed (AUC, 0.71 v 0.63) and platinum-exposed (AUC,0.68 v 0.58) survivors.A pleiotropic cancer PRS has strong potential for improving SMN clinical risk stratification among nonirradiated survivors treated with specific chemotherapies. A polygenic risk screening approach may be a valuable complement to an early screening strategy on the basis of treatments and rare cancer-susceptibility mutations.
Increased Frequency of Genetic Thrombophilia in Women with Complications of Pregnancy
Authors: Michael J. Kupferminc, Amiram Eldor, Nitzan Steinman, Ariel Many, Amiram Bar-Am, Ariel Jaffa, Gideon Fait, Joseph B. Lessing
Journal: New England Journal of Medicine (1999)

Obstetrical complications such as severe preeclampsia, abruptio placentae, fetal growth retardation, and stillbirth are associated with intervillous or spiral-artery thrombosis and inadequate placental perfusion. Whether these complications are associated with an increased frequency of thrombophilic mutations is not known.
Spinal-Fusion Surgery — The Case for Restraint
Authors: Richard A. Deyo, Alf Nachemson, Sohail K. Mirza
Journal: New England Journal of Medicine (2004)

The use of spinal-fusion surgery is increasing rapidly in the United States. Most of these expensive, complex procedures are now being done for back pain and degenerative disease. Spinal fusions require long operations and are associated with an increase in the rate of complications, particularly in older patients. The benefits of surgery may be only modest, and pain relief is affected by many factors besides the anatomy. The authors of this article argue for restraint in the use of spinal-fusion surgery and for controlled trials to define more clearly the associated benefits and the indications.
A Community-Based Outbreak of Infection with Penicillin-Resistant<i>Neisseria gonorrhoeae</i>Not Producing Penicillinase (Chromosomally Mediated Resistance)
Authors: Hawazin Faruki, Robert N. Kohmescher, W. Paul McKinney, P. Frederick Sparling
Journal: New England Journal of Medicine (1985)

Original Article from The New England Journal of Medicine — A Community-Based Outbreak of Infection with Penicillin-Resistant Neisseria gonorrhoeae Not Producing Penicillinase (Chromosomally Mediated Resistance)
Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted <scp>IL</scp>‐13 inhibition
Authors: Eric L. Simpson, Emma Guttman‐Yassky, Lawrence F. Eichenfield, Mark Boguniewicz, Thomas Bieber, Shannon Schneider, Adriana Guana, Jonathan I. Silverberg
Journal: Allergy (2023)

Abstract Atopic dermatitis (AD) is a chronic, inflammatory, intensely pruritic skin disorder associated with significant patient burden. Interleukin (IL)‐13 is a cytokine that acts as a driver of immune dysregulation, skin‐barrier dysfunction, and microbiome dysbiosis that characterizes AD, and is consistently overexpressed in AD skin. Tralokinumab is a fully human immunoglobulin (Ig) G4 monoclonal antibody that binds specifically to IL‐13 with high affinity, thereby inhibiting subsequent downstream IL‐13 signaling. Three pivotal phase 3 clinical trials demonstrated that tralokinumab 300 mg every other week, as monotherapy or in combination with topical corticosteroids as needed, provides significant improvements in signs and symptoms of moderate‐to‐severe AD, as measured by Investigator's Global Assessment 0/1 (clear/almost clear) and Eczema Area and Severity Index‐75 at Week 16. Improvements were observed soon after tralokinumab initiation and were maintained over 52 weeks of therapy. Tralokinumab significantly improved patient‐reported outcomes such as itch and sleep, and demonstrated a safety profile comparable with placebo; conjunctivitis during tralokinumab therapy was generally mild. Similar results were observed in a phase 3 adolescent trial. The role of IL‐13 in the pathophysiology of AD justifies a targeted approach and a wealth of clinical data supports tralokinumab as a new therapeutic option for people with moderate‐to‐severe AD.
Cardiopulmonary Impact of Electronic Cigarettes and Vaping Products: A Scientific Statement From the American Heart Association
Authors: Jason J. Rose, Suchitra Krishnan-Sarin, Vernat J. Exil, Naomi M. Hamburg, Jessica L. Fetterman, Fumito Ichinose, Miguel A. Perez-Pinzon, Mary Rezk-Hanna, Eric Williamson
Journal: Circulation (2023)

Vaping and electronic cigarette (e-cigarette) use have grown exponentially in the past decade, particularly among youth and young adults. Cigarette smoking is a risk factor for both cardiovascular and pulmonary disease. Because of their more limited ingredients and the absence of combustion, e-cigarettes and vaping products are often touted as safer alternative and potential tobacco-cessation products. The outbreak of e-cigarette or vaping product use-associated lung injury in the United States in 2019, which led to >2800 hospitalizations, highlighted the risks of e-cigarettes and vaping products. Currently, all e-cigarettes are regulated as tobacco products and thus do not undergo the premarket animal and human safety studies required of a drug product or medical device. Because youth prevalence of e-cigarette and vaping product use was as high as 27.5% in high school students in 2019 in the United States, it is critical to assess the short-term and long-term health effects of these products, as well as the development of interventional and public health efforts to reduce youth use. The objectives of this scientific statement are (1) to describe and discuss e-cigarettes and vaping products use patterns among youth and adults; (2) to identify harmful and potentially harmful constituents in vaping aerosols; (3) to critically assess the molecular, animal, and clinical evidence on the acute and chronic cardiovascular and pulmonary risks of e-cigarette and vaping products use; (4) to describe the current evidence of e-cigarettes and vaping products as potential tobacco-cessation products; and (5) to summarize current public health and regulatory efforts of e-cigarettes and vaping products. It is timely, therefore, to review the short-term and especially the long-term implications of e-cigarettes and vaping products on cardiopulmonary health. Early molecular and clinical evidence suggests various acute physiological effects from electronic nicotine delivery systems, particularly those containing nicotine. Additional clinical and animal-exposure model research is critically needed as the use of these products continues to grow.
Improved ambient air quality is associated with decreased prevalence of childhood asthma and infancy shortly after weaning is a sensitive exposure window
Authors: Tianyi Chen, Su Shi, Xinyue Li, Lu Zhou, Yongfu Yu, Yunfei Cai, Jing Wang, Haidong Kan, Yanyi Xu, Chen Huang, Yongqiang Tan, Xia Meng, Zhuohui Zhao
Journal: Allergy (2023)

Abstract Background The urban ambient air quality has been largely improved in the past decade. It is unknown whether childhood asthma prevalence is still increasing in ever top‐ranking city of Shanghai, whether the improved air quality is beneficial for children's asthma and what time window of exposure plays critical roles. Methods Using a repeat cross‐sectional design, we analyzed the association between early life exposure to particles and wheezing/asthma in each individual and combined surveys in 2011 and 2019, respectively, in 11,825 preschool children in Shanghai. Results A significantly lower prevalence of doctor‐diagnosed asthma (DDA) (6.6% vs. 10.5%, p &lt; 0.001) and wheezing (10.5% vs. 23.2%, p &lt; 0.001) was observed in 2019 compared to 2011. Exposure to fine particulate matter (PM 2.5 ), coarse particles (PM 2.5–10 ) and inhalable particles (PM 10 ) was decreased in 2019 by 6.3%, 35.4%, and 44.7% in uterus and 24.3%, 20.2%, and 31.8% in infancy, respectively. Multilevel log‐binomial regression analysis showed exposure in infancy had independent association with wheezing/DDA adjusting for exposure in uterus. For each interquartile range (IQR) increase of infancy PM 2.5 , PM 2.5–10 and PM 10 exposure, the odds ratios were 1.39 (95% confidence interval (CI): 1.24–1.56), 1.51 (95% CI:1.15–1.98) and 1.53 (95% CI:1.27–1.85) for DDA, respectively. The distributed lag non‐linear model showed the sensitive exposure window (SEW) was 5.5–11 months after birth. Stratified analysis showed the SEWs were at or shortly after weaning, but only in those with &lt;6 months of exclusive breastfeeding. Conclusions Improved ambient PM benefits in decreasing childhood asthma prevalence. We firstly reported the finding of SEW to PM at or closely after weaning on childhood asthma.
Meeting Unmet Needs in Chronic Obstructive Pulmonary Disease Diagnosis and Treatment in Low- and Middle-Income Countries
Authors: Obianuju B. Ozoh, Tochukwu Ayo-Olagunju, Kevin Mortimer
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"Meeting Unmet Needs in COPD Diagnosis and Treatment in Low- and Middle-Income Countries." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
Successful retrieval of a lumen-apposing metal stent that had completely migrated into the cavity of a walled-off necrosis
Authors: Sho Takahashi, Shigeto Ishii, Akinori Suzuki, Koichi Ito, Ko Tomishima, Toshio Fujisawa, Hiroyuki Isayama
Journal: Endoscopy (2023)

Endoscopic ultrasonography (EUS)-guided transgastric drainage of pancreatic fluid collections (PFCs) using a lumen-apposing metal stent (LAMS) is an effective treatment for walled-off necrosis (WON) [1] [2] [3]. However, misdeployment can occur, which is a severe adverse event [4] [5].